Peptide substance restoring myocardium function — US7662789B2
V. Kh. Khavinson, G. A. Ryzhak, E. I. Grigoriev, I. Yu. Ryadnova · 2010 · US patent 7,662,789 B2
What does this source report?
Original patent behind the rat-infarction claim in the 2023 cardiovascular review. Kept separate from clinical evidence and peer-reviewed primary experiments.
- Population and setting
- AEDR patent; myocardial experiments cited by the cardiovascular review
- Evidence type
- Patent / reported experiments
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Patent claims are not independent validation.
- No human cardiovascular benefit is established by this source.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Patent identity and its citation as reference 123 in the review checked; detailed experimental appraisal pending.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: V. Kh. Khavinson, G. A. Ryzhak, E. I. Grigoriev, I. Yu. Ryadnova. Peptide substance restoring myocardium function — US7662789B2 US patent 7,662,789 B2 2010.
Molekul research summary: https://molekul.io/research/bio-aedr-patent-2010. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry